Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | DRD1 | P21728 | 3/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1986102 | 0.86 | ABCB11 (0.46) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL954553 | 0.84 | DRD1 (0.47) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL1269320 | 0.84 | DRD1 (0.47) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL3077710 | 0.83 | DRD1 (0.46) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| Bromide SCHEMBL2087060 | 0.83 | DRD1 (0.46) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL3077705 | 0.83 | DRD1 (0.46) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL6615615 | 0.82 | DRD1 (0.45) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL5028770 | 0.81 | ABCB11 (0.46) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| SCHEMBL6208238 | 0.81 | ABCB11 (0.42) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 | |
| Sulfuric Acid SCHEMBL6363639 | 0.80 | ABCB11 (0.50) | ABCB11CYP2C19DRD1ADRA2ACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024114797-A1 | SOLID PREPARATION CONTAINING OXIDIZED CLOPIDOGREL AND PREPARATION METHOD THEREFOR | 成都施贝康生物医药科技有限公司 | 2024-06-06 | — | — | WO | disclosed |
| WO-2023241688-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND RESISTING BLOOD COAGULATION AND USE THEREOF | 成都施贝康生物医药科技有限公司 | 2023-12-21 | — | — | WO | disclosed |
| CN-116947743-A | Nitrosothiol compound and synthesis method and application thereof | 南京雷正医药科技有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-3766493-B1 | METHOD FOR IMPROVING THE STABILITY OF CLOPIDOGREL USING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116262116-A | Solid preparation containing clopidogrel oxide and preparation method thereof | 成都施贝康生物医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-115518066-A | Pharmaceutical composition for treating anticoagulation and application | 成都施贝康生物医药科技有限公司 | 2022-12-27 | — | — | CN | disclosed |
| EP-3766493-A1 | METHOD FOR IMPROVING THE STABILITY OF CLOPIDOGREL USING SULFOALKYL ETHER CYCLODEXTRIN | CyDex Pharmaceuticals, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-2152078-B1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS INC (US) | 2021-01-13 | — | — | EP | disclosed |
| US-10512697-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2019-12-24 | — | — | US | disclosed |
| CN-104800210-B | Preparation comprising clopidogrel and sulfoalkyl ether cyclodextrin and its application method | 锡德克斯药物公司 | 2019-08-06 | — | — | CN | disclosed |
| US-9125945-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| CN-104800210-A | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS INC | 2015-07-29 | — | — | CN | disclosed |
| CN-101686681-B | Formulations comprising clopidogrel and sulfoalkyl ether cyclodextrins and methods of use thereof | CYDEX PHARMACEUTICALS INC | 2015-04-01 | — | — | CN | disclosed |
| US-20150025243-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-01-22 | — | — | US | disclosed |
| US-8853236-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130129700-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8343995-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100292268-A1 | Formulations Containing Clopidogrel and Sulfoalkyl Ether Cyclodextrin and Methods of Use | CYDEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2152078-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CyDex Pharmaceuticals, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008134600-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025243-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYP2C19, CYP2C9, CYP3A7 | ABCB11 114/4885CYP2C19 1/4885DRD1 687/4885 |
| US-10512697-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYP2C19, CYP2C9, CYP3A7 | ABCB11 114/4885CYP2C19 1/4885DRD1 687/4885 |
| US-20130129700-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYP2C19, CYP2C9, CYP3A7 | ABCB11 114/4885CYP2C19 1/4885DRD1 687/4885 |
| US-20100292268-A1 | Formulations Containing Clopidogrel and Sulfoalkyl Ether Cyclodextrin and Methods of Use | CYP2C19, CYP2C9, CYP3A7 | ABCB11 114/4885CYP2C19 1/4885DRD1 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.